Better Therapeutics (BTTX) Competitors $0.0001 0.00 (0.00%) As of 02:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BTTX vs. UPHL, OPGN, ACONW, AONC, DHACW, FMS, LFMDP, OTRKP, PIIIW, and TALKWShould you be buying Better Therapeutics stock or one of its competitors? The main competitors of Better Therapeutics include UpHealth (UPHL), OpGen (OPGN), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), Fresenius Medical Care AG & Co. KGaA (FMS), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), and Talkspace (TALKW). These companies are all part of the "healthcare" industry. Better Therapeutics vs. Its Competitors UpHealth OpGen Aclarion American Oncology Network Digital Health Acquisition Fresenius Medical Care AG & Co. KGaA LifeMD Ontrak P3 Health Partners Talkspace Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Is BTTX or UPHL more profitable? Company Net Margins Return on Equity Return on Assets Better TherapeuticsN/A N/A N/A UpHealth N/A N/A N/A Which has preferable valuation & earnings, BTTX or UPHL? Better Therapeutics has higher earnings, but lower revenue than UpHealth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBetter TherapeuticsN/AN/A-$39.76MN/AN/AUpHealth$130M0.00-$56.42M-$1.350.00 Do institutionals & insiders believe in BTTX or UPHL? 34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 34.2% of UpHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, BTTX or UPHL? Better Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, UpHealth has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Does the media prefer BTTX or UPHL? In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score. Company Overall Sentiment Better Therapeutics Neutral UpHealth Neutral SummaryBetter Therapeutics beats UpHealth on 3 of the 5 factors compared between the two stocks. Get Better Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTTX vs. The Competition Export to ExcelMetricBetter TherapeuticsHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$70.71M$5.82B$9.75BDividend YieldN/AN/A3.84%4.09%P/E RatioN/AN/A31.1425.96Price / SalesN/A9.43475.48122.90Price / CashN/A4.0237.1558.38Price / BookN/A1.159.116.38Net Income-$39.76M-$30.80M$3.26B$265.56M7 Day PerformanceN/A-14.61%1.94%1.81%1 Month PerformanceN/A-1.46%4.91%1.14%1 Year PerformanceN/A525.29%31.21%20.98% Better Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTTXBetter TherapeuticsN/A$0.00flatN/A+0.0%$5KN/A0.0040UPHLUpHealthN/A$0.00flatN/A-100.0%$4K$130M0.001,750OPGNOpGenN/A$0.00flatN/A-100.0%$1K$2.67M0.00100ACONWAclarionN/A$0.05+15.7%N/A+62.2%$0.00$62.95K0.007Gap UpAONCAmerican Oncology NetworkN/A$11.06-10.8%N/A+246.5%$0.00$1.34B0.001,520Gap DownDHACWDigital Health AcquisitionN/A$0.03flatN/AN/A$0.00N/A0.00N/AFMSFresenius Medical Care AG & Co. KGaA2.8104 of 5 stars$25.19+0.8%$27.80+10.4%+32.8%$0.00$20.63B20.641,384News CoverageShort Interest ↑LFMDPLifeMDN/A$24.11+0.4%N/A+8.9%$0.00$245.56M0.00230Positive NewsOTRKPOntrakN/A$0.02+112.9%N/A-90.1%$0.00$10.84M0.00250Gap UpHigh Trading VolumePIIIWP3 Health PartnersN/A$0.01-0.9%N/A-55.9%$0.00$1.46B0.00500TALKWTalkspaceN/A$0.07-5.2%N/A+78.3%$0.00$202.61M0.00500Gap Down Related Companies and Tools Related Companies UPHL Alternatives OPGN Alternatives ACONW Alternatives AONC Alternatives DHACW Alternatives FMS Alternatives LFMDP Alternatives OTRKP Alternatives PIIIW Alternatives TALKW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Better Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access